Filed in archive
Drugs, Vaccines and Therapeutics
by ruth on July 3, 2006

Genetech officials say Lccentis is the first therapy to improve vision in wet AMD patients. Highlights of the pivotal clinical studies that led to this approval are discussed in the company press release. A reply of a webcast by the Genentech management on the approval may be accessed until July 7 at the company website. Access numbers for this replay are: 1-800-642-1687 (U.S./Canada) and 1-706-645-9291 (international); Conference ID number is 1794492.
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/26528
Mr Wong
Vote for FDA Approves Lucentis For Age-Related Vision Loss:
|
Rating: 8.67 out of 3 vote(s) cast.
|
Response from:
ThePharmVoice
Genentech, Inc.’s LUCENTIS™ (ranibizumab injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD) has recently been approved by the USFDA. The approval came after a Priority Review period of six months. Follo...
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







